Imaging Advances in Light Chain Amyloidosis.

Miaoling Qiu, Kaini Shen, Hua Yang, Jun Wang, Jian Li

Abstract readReview

In one paragraph

Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Miaoling QiuDepartment of Hematology, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China.ORCID 0000-0002-5726-4002

Kaini ShenDepartment of Hematology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Hua YangDepartment of Hematology, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China.

Jun WangDepartment of Hematology, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China.

Jian LiDepartment of Hematology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.ORCID 0000-0002-4549-0694

Funding

Sanming Project of Medicine in Shenzhen SZSM202311022Shenzhen Clinical Research Center for Rare Diseases LCYSSQ20220823091402005

6 · The paper itself

Abstract

Light chain (AL) amyloidosis is a systemic disorder caused by plasma cell dyscrasia, with cardiac involvement being the primary determinant of prognosis. Survival outcomes vary significantly across disease stages. This heterogeneity underscores a critical need for early diagnosis, precise risk stratification, and response-adapted therapy. In this context, multimodality imaging has emerged as an indispensable non-invasive tool, providing crucial insights for clinical decision-making. This review synthesizes recent advances in the application of key imaging modalities-echocardiography, magnetic resonance imaging, and nuclear medicine imaging-for evaluating AL amyloidosis. We highlight how these techniques have shifted the paradigm from anatomical assessment to quantitative, multiparametric tissue characterization, ultimately guiding personalized patient management.

Indexed as

cardiac amyloidosisechocardiographyintegrating artificial intelligencelight chain amyloidosismagnetic resonance imagingmultimodal imagingnuclear medicine imaging

Identifiers

PMID42510088

DOI10.3390/diagnostics16142225

PMCPMC13409453

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.